Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
10.12025/j.issn.1008-6358.2025.20251534
- VernacularTitle:前列腺癌177Lu-PSMA-617放射配体疗法研发历程、药物特性及临床应用
- Author:
Jing LÜ
1
;
Guobing LIU
1
;
Hongcheng SHI
1
Author Information
1. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Review
- Keywords:
prostate cancer;
radioligand therapy;
prostate specific membrane antigen;
lutetium-177;
177Lu-PSMA-617
- From:
Chinese Journal of Clinical Medicine
2026;33(2):321-329
- CountryChina
- Language:Chinese
-
Abstract:
Lutetium-177 (177Lu)-prostate specific membrane antigen (PSMA)-617 is a small-molecule radioligand therapy (RLT) drug targeting PSMA. By selectively delivering the β－ radiation emitted by 177Lu to PSMA-positive prostate cancer cells, it induces tumor cell death. The agent has been approved in multiple nations and regions for the treatment of PSMA-positive metastatic castration-resistant prostate cancer, thereby expanding therapeutic options for this patient population. This review outlines the development, pharmacological properties, and current clinical applications of 177Lu-PSMA-617, aiming to provide a theoretical basis for the clinical practice of RLT in prostate cancer treatment.
